Market Overview

UPDATE: Bank of America Upgrades Celgene to Buy on Improving Growth Outlook

Share:
Related CELG
Orphan Drugs Among 2015's Top 10 Best-Selling Medications
Oppenheimer Upgrades Agios Pharma On Expectations For First Drug Launch
Raymond James Trust N.a. Buys WisdomTree Japan Hedged Equity Fund, United Technologies Corp, ... (GuruFocus)

Bank of America upgraded Celgene Corporation (NASDAQ: CELG) from Neutral to Buy and raised the price target from $88.00 to $115.00.

Bank of America commented, "We are upgrading CELG from Neutral to Buy and increasing our PO from $88 to $115 (16x2014E) following a series of model changes that show CELG should grow sales by a minimum of 14% and EPS by 25% CAGR over the next 5 yrs. We have increased conviction in CELG's long term growth profile driven by multiple growth products, and believe shares will continue to experience PE expansion over 2013 driven by: (1) positive Abraxane data (Jan 24-26), (2) better Pomalyst pricing and product launch vs. Street consensus, and (3) visibility on CELG's emerging pipeline, incl novel imids with potential positive Revlimid life cycle implications."

Celgene closed at $97.67 on Monday.

Latest Ratings for CELG

DateFirmActionFromTo
Nov 2016OppenheimerInitiates Coverage OnOutperform
Nov 2016Standpoint ResearchDowngradesBuyHold
Nov 2016MizuhoInitiates Coverage OnBuy

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (CELG)

View Comments and Join the Discussion!